Gridelli C, et al. - Researchers investigated the efficacy and safety of continuous bevacizumab treatment beyond disease progression in patients with non–small cell lung cancer (NSCLC). Bevacizumab (7.5 or 15 mg/kg intravenously every 21 days) and/or investigator’s choice of standard of care (SOC) was provided in this randomized clinical trial of 485 patients with advanced, nonsquamous NSCLC. The primary outcome of overall survival (OS) was not met; the groups were not significantly different in terms of median overall survival. Bevacizumab treatment beyond disease progression did not induce new safety signals. Findings thus suggest no survival benefits with continued bevacizumab treatment beyond disease progression.